REPL - Replimune Scraps RP2 and RP3 Clinical Programs After Phase 2 Miss; Shares Collapse Nearly 76%

2025-07-22 15:00:51 ET

Replimune Group ( REPL ) shares plummeted over 75% in trading today after the company announced the discontinuation of its RP2 and RP3 programs . The decision follows disappointing results from the Phase 2 CERPASS clinical trial, which tested RP1 in combination with Libtayo in advanced cutaneous squamous cell carcinoma (CSCC).

The trial failed to meet its primary endpoint of complete response rate as determined by independent review. Secondary endpoints, including overall response rate and duration of response, also failed to show meaningful improvements over the control group. As a result, the company will no longer pursue development of RP2 or RP3, which had been in earlier-stage trials.

Replimune said it will now shift focus exclusively to RP1. The drug remains in evaluation for less advanced CSCC in the Phase 3 IGNYTE trial, which the company expects to report top-line data from in the first half of 2025. The company emphasized that it still sees RP1 as having potential in earlier lines of therapy, particularly in settings without systemic immune checkpoint inhibitor pretreatment.

Replimune's cash runway remains strong, with $385 million on hand as of the end of June 2025. The company projects this funding will support operations through 2027, even as it narrows its clinical priorities.

The post Replimune Scraps RP2 and RP3 Clinical Programs After Phase 2 Miss; Shares Collapse Nearly 76% appeared first on PRISM MarketView .

COMTEX_467483971/2927/2025-07-22T14:00:51